Technology

ARIBIOLAB Soars Amid AI-Driven Stock Market Turmoil… SEERS and InBody Co., Ltd. Hindered by Earnings [Bio Spotlight]

KIM SAE-MI
2026-11-08 08:40:03
[Edaily Reporter KIM SAE-MI ] On the 6th, as the domestic stock market wavered amid concerns over artificial intelligence (AI), biotech and healthcare stocks also generally failed to escape the downtrend. Amid this, ARIBIOLAB (formerly CHA Vaccine Research Institute(261780)) rose more than 11% on expectations of a merger with its unlisted affiliate, AriBio. In contrast, SEERS TECHNOLOGY(458870)hit the daily price limit down following weak third-quarter earnings, while InBody Co., Ltd.(041830)saw its stock price plunge 27% as net income was cut in half despite a surge in operating profit.

Recent ARIBIOLAB Stock Price Trends (Source: KG Zeroin MP Doctor)

ARIBIOLAB Up 11.7% on Merger Expectations… Betting 10 Billion on 5 Billion Convertible Bonds (CB)
According to KG Zeroin MP Doctor (MP DOCTOR) on that day, ARIBIOLAB closed at 4,300 won, up 450 won (11.69%) from the previous day. This is believed to have stimulated investor sentiment as speculation arose about a potential merger between the two companies, following AriBioLab’s acquisition of convertible bonds (CBs) issued by its unlisted affiliate, AriBio. Trading volume on that day reached 3,195,391 shares, more than double the volume recorded on the 4th (1,435,302 shares).

Previously, on the 4th, ARIBIOLAB announced in a regulatory filing that it had decided to acquire 5 billion won worth of AriBio’s 26th series of convertible bonds (CBs) for 10 billion won. This represents twice the face value, and the acquisition amount accounts for 84.32% of ARIBIOLAB’s equity. The conversion price for these convertible bonds is 10,000 won per share; if converted in full, ARIBIOLAB would secure 500,000 shares of AriBio stock. On the day of the announcement, ARIBIOLAB’s stock price surged 18.71% to 3,965 won.

This transaction is drawing attention as it coincides with the AriBio Group’s efforts to restructure its corporate governance. On September 18, ARIBIOLAB decided to conduct a third-party private placement worth 18 billion won. Under this structure, AriBio will contribute 15 billion won, and AriBio Holdings will contribute 3 billion won.

Once the capital increase payment is completed on the 30th, ARIBIOLAB’s largest shareholder is expected to shift from AriBio Holdings to AriBio. This means that while AriBio will become the largest shareholder of its listed affiliate, ARIBIOLAB will secure a potential stake in AriBio through the convertible bonds.

On the same day, a media outlet reported speculation that AriBio might be considering ARIBIOLAB as a new merger target. This has been interpreted as a preliminary step toward a future backdoor listing or merger, aimed at strengthening the shareholding ties among affiliates.

In response, an AriBio official stated, “While the convertible bond acquisition is true, the details regarding the merger appear to be the media outlet’s interpretation,” adding, “We have no information on this matter.”

Another factor that could influence the stock price in the future is the results of the global Phase 3 clinical trial for AriBio’s Alzheimer’s disease treatment, “AR1001.” AriBio is scheduled to announce the topline results of the global Phase 3 clinical trial for AR1001 at the Clinical Trials in Alzheimer’s Disease (CTAD) conference, to be held in Boston, U.S., on the 16th.

An AriBio official noted, “As we are currently preparing for the topline announcement, the company is focusing its resources on that effort.”

Recent SEERS Stock Price Trends (Source: KG Zeroin MP Doctor)

SEERS Pl
umm
ets After Posting Third-Quarter Loss… Hit Hard by Server Supply Disruptions
On this day
, SEERS
closed at 14,500 won
,
plummeting 6,200 won (29.95%) from the previous day. The stock hit the daily price limit down after the company reported weak third-quarter results, including a year-over-year decline in revenue and a shift to losses in both operating and net income.

SEERS announced that its consolidated operating loss for the third quarter was 1.9 billion won, marking a shift to a loss from a 6.7 billion won profit in the same period last year. Revenue for the same period fell 38% to 9.8 billion won, and net loss stood at 1.9 billion won, reversing a 6.7 billion won net profit from the prior-year period. This indicates that profitability has deteriorated alongside the decline in revenue.

The company attributed the poor performance to supply chain disruptions for servers required for “thynC,” its flagship artificial intelligence (AI) bedside monitoring platform. Delays in securing the servers needed for thynC supply disrupted the product installation schedule and revenue recognition timelines.

The company emphasized that its cumulative performance for the year continues to show significant growth. SEERS’ cumulative revenue for the first three quarters reached 70.7 billion won, a 155% increase from 27.8 billion won in the same period last year. During the same period, cumulative operating profit rose 226.7% to 24.9 billion won, and cumulative net profit also increased by 225.0% to 24.8 billion won.

This means that the strong performance seen through the first half of the year came to a sharp halt in the third quarter. SEERS reported that it completed server deliveries at the end of last month and is currently proceeding with installations at each hospital in sequence. The company plans to diversify its supply chain by collaborating with major manufacturers such as Dell, HP, and Lenovo, as well as by pursuing original equipment manufacturer (OEM) contracts.

Lee Young-shin, CEO of SEERS, stated, “We take seriously the concern we have caused our shareholders and investors by posting results that fell short of expectations due to server supply disruptions in the third quarter.” He added, “We will focus on recovering our performance in the fourth quarter by normalizing server supply and ensuring a stable product supply, and we will do our utmost to achieve sustained growth and enhance shareholder value.”

Recent InBody Co.
,
Ltd. Stock Price Trends (Source: KG Zeroin MP Doctor)

InBody Co., Ltd.: Operating Profit Doubles, but Stock Price Drops 27%… Controversy Over “Quality of Earnings”
On that day, InBody Co., Ltd. closed at 41,750 won, a sharp drop of 15,550 won (27.14%) from the previous day. Just one day after surging 23.89%, the stock gave up all its gains and fell further. Selling pressure was so intense that the stock briefly approached the daily price limit during the trading session.

This is interpreted as a deterioration in investor sentiment following analyses suggesting that, although both revenue and operating profit increased in the third quarter of this year, net profit was cut in half, and the improvement in operating profit was partly due to temporary accounting effects.

On the 5th, InBody Co., Ltd. announced that its preliminary consolidated operating profit for the third quarter surged 95.6% year-over-year to 19.3 billion won. While revenue for the same period rose 19.2% to 71.3 billion won, net income fell 53.1% to 4.4 billion won. This means that despite revenue growth and an improvement in operating profit, net income declined significantly.

Some analysts in the securities industry have suggested that the sharp rise in operating profit cannot be viewed as a genuine improvement in profitability.

KIWOOM Securities analyzed that the operating profit margin was driven up by a decrease in cost of sales due to a weaker exchange rate and adjustments to unrealized gains related to inventory assets. While the actual third-quarter operating profit margin reached 27.1%, the firm estimated that the normalized operating profit margin—excluding these effects—was 19.5%. This is lower than the second quarter’s normalized operating profit margin of 20.3%.

The decline in net income is believed to have been influenced by a deterioration in non-operating income and expenses. With net income totaling only 4.4 billion won compared to operating income of 19.3 billion won, analysts point out the need to examine the impact of non-operating expenses and corporate income tax.

Nevertheless, cumulative performance continued to show growth. Cumulative revenue for the first three quarters of this year reached 213 billion won, a 24.1% increase year-over-year, while operating profit rose 83.9% to 50.1 billion won. Cumulative net profit also increased by 49.1% to 35.2 billion won.

In the fourth quarter, profitability is expected to decline as the temporary factors that boosted third-quarter results disappear and year-end expenses are reflected.

Shin Min-soo, an analyst at KIWOOM Securities, stated, “Since there will be no tariff refunds in the fourth quarter and the impact of exchange rates is expected to decrease compared to the third quarter, we forecast the gross profit margin to be 76.5%.” He added, “Taking into account the seasonality of costs, such as year-end performance bonuses, we expect the operating profit margin to be 15.8%.”

Economy

Corporation

IT·Science

Economy

[37th SRE][Issue] BBB-Rated Market Stifled by the JR and JoongAng Crisis

“The bond market should be a universal channel for corporate financing, but right now it’s like an exclusive social club.”This was the point raised by an advisory committee member during a meeting hel…
2026-11-18 10:30:05

Corporation

'Gyochon Makgeolli' Served at APEC Banquet… Available at the Grand Hyatt Hotel

KYOCHON FOOD&BEVERAGE, operator of the Kyochon Chicken franchise, is expanding its sales channels for traditional Korean liquor by introducing its premium makgeolli, “Eunhwasu: A Night of Stargazing 1…
2026-11-18 09:50:52

IT·Science

SillaJen, Inc.’s Anticancer Virus ‘SJ-650’ Selected for National New Drug Development Project… Moving Forward with Preclinical Trials

SillaJen, Inc.(215600)The company is receiving government support for the development of “SJ-650,” a next-generation anticancer viral therapy administered via intravenous injection. It plans to accele…
2026-11-18 10:02:02